There are anecdotal reports that some Cannabis preparations may be useful for bladder dysfunctions. Here, we investigated the effect of a number of non-psychotropic phytocannabinoids, namely cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabichromene (CBC) on mouse bladder contractility in vitro. CBG, THCV, CBD and CBDV, but not CBC, at concentration ranging from 10−8 M to 10−4 M, decreased (with similar potency), the contractions induced by acetylcholine without significantly modifying the contractions induced by electrical stimulation. The rank order of efficacy was CBG=THCV>CBD>CBDV. In depth studies on CBG showed that the effect of this phytocannabinoid on acetylcholine-induced contractions was not affected by CB1 or CB2 receptor antagonists. Additionally, CBG also reduced acetylcholine-induced contractions in the human bladder.
RuggieriMRSr. (2011) Cannabinoids: potential targets for bladder dysfunction. Handbook of Experimental Pharmacology, (202), 425–51
2.
MehmedicZ, ChandraS, SladeD, DenhamH, FosterS, PatelAS, RossSA, KhanIA, El SohlyMA. (2010) Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. Journal of Forensic Sciences, 55, 1209–1217.
3.
HillAJ, WilliamsCM, WhalleyBJ, StephensGJ. (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology and Therapeutics, 133, 79–97.
4.
PertweeRG, FernandoSR. (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. British Journal of Pharmacology, 118, 2053–2058.
5.
MartinRS, LuongLA, WelshNJ, EglenRM, MartinGR, MacLennanSJ. (2000) Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. British Journal of Pharmacology, 129, 1707–1715.
6.
GratzkeC, StrengT, StiefCG, DownsTR, AlroyI, RosenbaumJS, AnderssonKE, HedlundP. (2010) Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. European Urology, 57, 1093–1100.
7.
CapassoR, AvielloG, BorrelliF, RomanoB, FerroM, CastaldoL, MontanaroV, AltieriV, IzzoAA. (2011) Inhibitory effect of standardized Cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. Urology, 77, 1006e9–1006e15.
8.
AlexanderSP, BensonHE, FaccendaE, PawsonAJ, SharmanJL, SpeddingM, PetersJA, HarmarAJ, CollaboratorsCGTP (2013) The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. British Journal of Pharmacology, 170, 1459–1581.
9.
de MeijerEP, BagattaM, CarboniA, CrucittiP, MoliterniVM, RanalliP, MandolinoG. (2003) The inheritance of chemical phenotype in Cannabis sativa L. Genetics, 163, 335–346.
10.
de MeijerEPM, HammandKM, MichelerM. (2009) The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion. Euphytica, 165, 293–311.
11.
de MeijerEPM, HammandKM. (2005) The inheritance of chemical phenotype in Cannabis sativa L. (II): cannabigerol predominant plants. Euphytica, 145, 189–198.
12.
RomanoB, BorrelliF, PaganoE, CascioMG, PertweeRG, IzzoAA. (2014) Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine, 21, 631–639.
13.
BorrelliF, PaganoE, RomanoB, PanzeraS, MaielloF, CoppolaD, De PetrocellisL, BuonoL, OrlandoP, IzzoAA. (2014) Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35, 2787–2797.
14.
ConsroeP, MustyR, ReinJ, TilleryW, PertweeR. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology, 38, 44–48.
15.
KoppelBS, BrustJC, FifeT, BronsteinJ, YoussofS, GronsethG, GlossD. (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82, 1556–1563.
16.
IzzoAA, CapassoR, AvielloG, BorrelliF, RomanoB, PiscitelliF, GalloL, CapassoF, OrlandoP, Di MarzoV. (2012) Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. British Journal of Pharmacology, 166, 1444–1460.
17.
CascioMG, GausonLA, StevensonLA, RossRA, PertweeRG. (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159, 129–141.
18.
De PetrocellisL, LigrestiA, MorielloAS, Allara‘M, BisognoT, PetrosinoS, StottCG, Di MarzoV. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163, 1479–1494.
19.
BorrelliF, FasolinoI, RomanoB, CapassoR, MaielloF, CoppolaD, OrlandoP, BattistaG, PaganoE, Di MarzoV, IzzoAA. (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85, 1306–1316.
20.
HedlundP. (2014) Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourology and Urodynamics, 33, 46–53.
